Serum interleukin measurement may help identify thyroid cancer patients with active disease |
| |
| Institution: | 1. Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126, Tessalia Vieira de Camargo St., Campinas, SP, Brazil;2. Division of Nuclear Medicine, Department of Radiology, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 251, Vital Brazil St., Campinas, SP, Brazil;3. Division of Endocrinology, Department of Medicine, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 251, Vital Brazil St., Campinas, SP, Brazil;1. Roche Diagnostics Corporation, Scientific Affairs – Cardiac, United States;2. Roche Diagnostics Corporation, Cardiac & Critical Care, Switzerland;3. Roche Diagnostics Corporation, Cardiovascular Disease, Switzerland;1. Department of Adult Cardiology, Deutsches Herzzentrum München, Technische Universität, Munich, Germany;2. Department of Laboratory Medicine, Deutsches Herzzentrum München, Technische Universität, Munich, Germany;3. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany;4. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany;1. Department of Pathology and Laboratory Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA;2. Departments of Biostatistics and Computational Biology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA;3. Departments of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, RB 9700, The Netherlands;4. Departments of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, RB 9700, The Netherlands |
| |
| Abstract: | BackgroundInvestigate the clinical utility of serum interleukin dosages of IL-2, IL-2R, IL-4, IL-6, IL-6R, IL-8, IL-10 and IL-12 in the diagnosis and characterization of patients with DTC. In particular, verify ILs utility in the identification of individuals who are evolving disease-free or with the active disease.MethodsWe evaluated 200 patients with malignant nodules (100 patients disease-free and 100 patients with recurrence/active disease); 60 benign nodules and 100 healthy controls, serum levels were assessed by ELISA.ResultsAll ILs, but not IL-4, differentiated these three groups. We observed that IL-2, 2R and 10 serum concentrations were associated with thyroglobulin levels. Serum IL-2 was able to differentiate patients with active disease from the disease-free with a sensitivity of 98%, specificity of 58%, positive predictive value (PPV) of 70% and negative predictive value (NPV) of 97% (p = 0.0007). IL-6R levels differentiated patients with active disease from the disease-free patients with 56% sensitivity, 63% specificity, PPV of 60% and NPV of 59% (p < 0.0001). IL-8 values also distinguished patients with active disease from the disease-free ones with sensitivity of 50%, specificity of 76%, PPV of 68% and NPV of 60% (p = 0.0025); using IL-12, we obtained a sensitivity value of 73%, specificity of 66%, PPV of 68% and NPV of 71% (p < 0.0001). Furthermore, interleukin levels showed association with some tumor characteristics of aggressiveness.ConclusionWe suggest that the serum concentration of ILs may assist in the diagnosis and characterization of tumor malignancy helping identify patients with active disease who deserve closer medical attention. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
